Page last updated: 2024-11-08

colfosceril palmitate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

colfosceril palmitate: used in the treatment of unilateral pulmonary interstitial emphysema; component of Exosurf [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

1,2-dihexadecanoyl-sn-glycero-3-phosphocholine : A phosphatidylcholine 32:0 in which the 1- and 2-acyl groups are specified as hexadecanoyl (palmitoyl). A synthetic phospholipid used in liposomes and lipid bilayers to study biological membranes. It is also a major constituent of pulmonary surfactants. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID452110
CHEMBL ID1200737
CHEBI ID72999
SCHEMBL ID24980
MeSH IDM0217563

Synonyms (151)

Synonym
MLS000028586
smr000058951
1,2-dipalmitoyl-sn-glycero-3-phosphocholine
colfosceril palmitate (usan/inn)
D03585
63-89-8
2-[[(2r)-2,3-di(hexadecanoyloxy)propoxy]-hydroxy-phosphoryl]oxyethyl-trimethyl-ammonium
dipalmitoylphosphatidylcholine
1,2-diacyl-sn-glycero-3-phoshocholine
1,2-dihexadecanoyl-sn-glycero-3-phosphocholine
dipalmitoyl-phosphatidylcholine
LMGP01010564
pc(16:0/16:0)
1,2-dipalmitoyl-l-lecithin
1,2-dipalmitoyl-3-sn-phosphatidylcholine
1,2-dipalmitoyl-sn-glycero-3-phosphocholine, >=99% (tlc)
1,2-dipalmitoyl-sn-glycero-3-phosphocholine, semisynthetic, >=99%
colfosceril palmitate
NCGC00167568-01
1,2-dipalmitoyl-phosphatidylcholine
16:0-16:0-pc
1-16:0-2-16:0-phosphatidylcholine
[(2r)-2,3-di(hexadecanoyloxy)propyl] 2-(trimethylazaniumyl)ethyl phosphate
dppc, l-
dppc, r-
129-y-83
129y83
chebi:72999 ,
dipalmitoyl glycerophosphocholine
CHEMBL1200737
dipalmitoyl lecithin, l-
dtxsid5046720 ,
tox21_112563
dtxcid3026720
cas-63-89-8
D3925
HMS2231H14
gpc(16:0/16:0)
c40h80no8p
phosphatidylcholine(16:0/16:0)
(2r)-2,3-bis(hexadecanoyloxy)propyl 2-(trimethylazaniumyl)ethyl phosphate
dipalmitoyl-gpc
l-a-dipalmitoyl lecithin
phosphatidylcholine 16:0/16:0
AKOS016013969
colfoscerili palmitas
unii-319x2nfw0a
palmitato de colfoscerilo
(r)-(4-oxido-10-oxo-7-palmitoyl-3,5,9-trioxa-4-phosphapentacosyl)trimethylammonium 4-oxide
choline hydroxide, dihydrogen phosphate, inner salt, ester with l-1,2-dipalmitin
3,5,9-trioxa-4-phosphapentacosan-1-aminium, 4-hydroxy-n,n,n-trimethyl-10-oxo-7-((1-oxohexadecyl)oxy)-, hydroxide, inner salt, 4-oxide, (r)-
colfoscerili palmitas [inn-latin]
319x2nfw0a ,
einecs 200-567-6
palmitato de colfoscerilo [inn-spanish]
palmitate de colfosceril
colfosceril palmitate [usan:inn:ban]
palmitate de colfosceril [inn-french]
1,2-dipalmitoyl-sn-glycero-3-phosphorylcholine
1,2-dihexadecanoyl-sn-glycero-3-phosphorylcholine
colfosceril [vandf]
1.2 dipalmitoyl-sn-glycero-3-phosphatidylcholine
colfosceril palmitate component of exosurf neonatal
1.2 dipalmitoyl-sn-glycero-3-phosphatidylcholine (dppc)
colfosceril palmitate [vandf]
colfosceril palmitate [usan]
op-0201 component colfosceril palmitate
colfosceril palmitate [who-dd]
surfaxin component dppc
dipalmitoyl glycerophosphocholine [inci]
exosurf neonatal component colfosceril palmitate
colfosceril palmitate [mi]
lucinactant component dppc
colfosceril palmitate [inn]
op0201 component colfosceril palmitate
colfosceril palmitate [orange book]
phosphatidylcholine(32:0)
pc 32:0
SCHEMBL24980
l-dipalmitoyl lecithin
(r)-2,3-bis(palmitoyloxy)propyl (2-(trimethylammonio)ethyl) phosphate
HMS3650O14
mfcd00036903
DB09114
colfoscerilpalmitat
(2-{[2.3-bis(hexadecanoyloxy)propyl phosphono]oxy}ethyl)trimethylazanium
1,2-dipalmitoyl-sn-3-glycerophosphocholine
1,2-dipalmitoyl-l-alpha-phosphatidylcholine
dipalmitoyl l-alpha-phosphatidylcholine
(r)-4-hydroxy-n,n,n-trimethyl-10-oxo-7-[(1-oxohexadecyl)oxy]-3,5,9-trioxa-4-phosphapentacosan-1-aminium 4-oxide inner salt
1,2-bis(palmitoyl)-sn-glycero-3-phosphocholine
l-b,g-dipalmitoyl-alpha-lecithin
b,g-dipalmitoyl l-a-phosphatidylcholine
l-1,2-dipalmitoylphosphatidylcholine
l-alpha-dipalmitoylphosphatidylcholine
l-dppc
l-a-dppc
1,2-dipalmitoyl-sn-glyceryl-3-phosphocholine
l-alpha-dppc
1,2-dipalmitoylglycero-3-phosphocholine
l-a-dipalmitoylecithin
1,2-bis(hexadecanoyl)-sn-glycero-3-phosphocholine
1,2-dipalmitoyl-sn-phosphatidylcholine
l-b,g-dipalmitoyl-a-lecithin
dihexadecanoyl-sn-glycero-3-phosphocholine
1,2-dipalmitoyl-l-a-phosphatidylcholine
l-1,2-dipalmitoyl-alpha-lecithin
l-alpha-dipalmitoyllecithin
dipalmitoyl-l-alpha-lecithin
1,2-dipalmitoyl-sn-glycerol-3-phosphocholine
l-b,g-dipalmitoyl-a-phosphatidylcholine
1,2-dipalmitoyl-sn-glycerophosphocholine
l-1,2-dipalmitoyl-a-lecithin
l-a-1,2-dipalmitoyl lecithin
1,2-l-alpha-dipalmitoylphosphatidylcholine
l-a-dipalmitoyllecithin
1,2-dipalmitoyl-l-3-phosphatidylcholine
dipalmitoyl-l-a-phosphatidylcholine
dipalmitoyl-l-3-glycerylphosphorylcholine
b,g-dipalmitoyl-l-phosphatidylcholine
dipalmitoyl-sn-3-phosphatidylcholine
1,2-dipalmitoyl-sn-glycerophosphorylcholine
l-alpha-dipalmitoylecithin
sn-3-dipalmitoyllecithin
l-a-dipalmitoylphosphatidylcholine
l-alpha-1,2-dipalmitoyl lecithin
dipalmitoyl-l-a-lecithin
1,2-dipalmitoyl-l-alpha-lecithin
1,2-l-a-dipalmitoylphosphatidylcholine
(r)-4-hydroxy-n,n,n-trimethyl-10-oxo-7-[(1-oxohexadecyl)oxy]-3,5,9-trioxa-4-phosphapentacosan-1-aminium 4-oxide hydroxide inner salt
1,2-dipalmitoyl-l-phosphatidylcholine
dipalmitoyl l-a-phosphatidylcholine
1,2-dihexadecanoyl-sn-glycerol-3-phosphorylcholine
l-b,g-dipalmitoyl-alpha-phosphatidylcholine
dipalmitoyl-l-alpha-phosphatidylcholine
b,g-dipalmitoyl-l-(a)-lecithin
1,2-dipalmitoyl-l-a-lecithin
b,g-dipalmitoyl l-alpha-phosphatidylcholine
l-b,g-dipalmitoylphosphatidylcholine
dppc;l-,-dipalmitoyl--lecithin
16:0 pc (dppc), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine, powder
(r)-2,3-bis(palmitoyloxy)propyl 2-(trimethylammonio)ethyl phosphate
(2r)-2,3-bis(hexadecanoyloxy)propyl 2-(trimethylammonio)ethyl phosphate
Q5144764
(2-{[(2r)-2,3-bis(hexadecanoyloxy)propyl phosphonato]oxy}ethyl)trimethylazanium
CS-0031214
HY-109506
AMY37583
H10481
colfoscerilpalmitate
EN300-7365657

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"Various xenobiotics interact with biological membranes, and precise evaluations of the molecular interactions between them are essential to foresee the toxicity and bioavailability of existing or newly synthesized molecules."( Probing nanomechanical interaction at the interface between biological membrane and potentially toxic chemical.
Hwang, DS; Ko, J; Lee, DW; Lim, C; Park, J; Park, S, 2018
)
0.48
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" There were no significant differences among the three dosage groups in mortality rate, air leak, bronchopulmonary dysplasia, and other complications of prematurity."( Comparison of the effect of three doses of a synthetic surfactant on the alveolar-arterial oxygen gradient in infants weighing > or = 1250 grams with respiratory distress syndrome. American Exosurf Neonatal Study Group II.
Berry, DD; Buchter, DS; Easa, D; Edwards, K; Kanarek, KS; Kopelman, AE; Long, W; Philips, JB; Pramanik, AK, 1994
)
0.29
" Further research needs to be performed to determine the optimal dosing and timing of these agents, as well as comparative trials studying efficacy."( Exogenous surfactant use in neonates.
Ishisaka, DY, 1996
)
0.29
" The results from this study can be applied as a model for the development of a gene-therapeutic dosage form."( Expression of luciferase plasmid (pCMVLuc) entrapped in DPPC/cholesterol/DDAB liposomes in HeLa cell lines.
Manosroi, A; Manosroi, J; Peschka-Süss, R; Schubert, R; Thathang, K; Werner, RG, 2009
)
0.35
" At maximum dosage and time (15 μM and 96 h), Sorafenib-loaded PLGA and HMC-coated liposomes killed 88."( Comparison of sorafenib-loaded poly (lactic/glycolic) acid and DPPC liposome nanoparticles in the in vitro treatment of renal cell carcinoma.
Arora, J; Boonkaew, B; Callaghan, C; Chava, S; Dash, S; He, J; John, VT; Lee, BR; Liu, J; Maddox, MM; Mandava, SH, 2015
)
0.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
surfactantA substance which lowers the surface tension of the medium in which it is dissolved, and/or the interfacial tension with other phases, and, accordingly, is positively adsorbed at the liquid/vapour and/or at other interfaces.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
phosphatidylcholine 32:0A 1,2-diacyl-sn-glycero-3-phosphocholine in which the acyl groups at C-1 and C-2 contain 32 carbons in total with 0 double bonds.
1-acyl-2-hexadecanoyl-sn-glycero-3-phosphocholineA 1,2-diacyl-sn-glycero-3-phosphocholine where the acyl group at position 1 is unspecified while the acyl group at position 2 is palmitoyl.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (10)

PathwayProteinsCompounds
Phospholipid Biosynthesis2529
Choline Metabolism1827
Lysolipid incorporation into Mitochondria PC(16:0/16:0)515
Lysolipid Incorporation into ER PC(16:0/16:0)1024
Phosphatidylcholine biosynthesis PC(16:0/16:0)27
Phosphatidylcholine Biosynthesis PC(16:0/16:0)620
Phosphatidylethanolamine Biosynthesis PE(16:0/16:0)516
phospholipid remodeling (phosphatidylcholine, yeast)07
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(16:0/16:0) | PE(16:0/16:0)617
phospholipid remodeling (phosphatidylcholine, yeast)38
phospholipid remodeling (phosphatidylcholine)48
Acetylcholine synthesis05

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.00050.003245.467312,589.2998AID2517
Chain A, Beta-lactamaseEscherichia coli K-12Potency0.35480.044717.8581100.0000AID485294
estrogen nuclear receptor alphaHomo sapiens (human)Potency37.57800.000229.305416,493.5996AID743079
survival motor neuron protein isoform dHomo sapiens (human)Potency1.77830.125912.234435.4813AID1458
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (153)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's7 (4.58)18.2507
2000's7 (4.58)29.6817
2010's124 (81.05)24.3611
2020's15 (9.80)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 42.60

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index42.60 (24.57)
Research Supply Index5.08 (2.92)
Research Growth Index5.93 (4.65)
Search Engine Demand Index59.66 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (42.60)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (1.92%)5.53%
Reviews6 (3.85%)6.00%
Case Studies2 (1.28%)4.05%
Observational0 (0.00%)0.25%
Other145 (92.95%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]